Recent advances in synthetic pharmacotherapies for dyslipidaemias

Medicine and Dentistry

• Low Density Lipoprotein Cholesterol 100%
• Dyslipidemia 100%
• Drug Therapy 100%
• Cardiovascular System 66%
• Triacylglycerol 66%
• High Density Lipoprotein Cholesterol 66%
• Statin 66%
• Hypertriglyceridemia 66%
• Biological Product 33%
• Supplementation 33%
• Mental Capacity 33%
• Receptor 33%
• Secondary Prevention 33%
• Omega-3 Fatty Acid 33%
• Creatinine 33%
• Drug Megadose 33%
• Low Drug Dose 33%
• Side Effect 33%
• Homocysteine 33%
• Oxidoreductase 33%
• Glucose Metabolism 33%
• Hypercholesterolemia 33%
• Apolipoprotein B100 33%
• Cholesterol Ester Transfer Protein 33%
• Cholesterol Ester 33%
• Probucol 33%
• Anacetrapib 33%
• Pitavastatin 33%
• Bempedoic Acid 33%
• Dicarboxylic Acid 33%
• Gemcabene 33%
• Pemafibrate 33%
• Triglyceride-Rich Lipoprotein 33%
• Lipoprotein 33%
• Atherogenesis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacotherapy 100%
• Triacylglycerol 100%
• Low Density Lipoprotein Cholesterol 100%
• Dyslipidemia 100%
• High Density Lipoprotein Cholesterol 66%
• Hypertriglyceridemia 66%
• Receptor 33%
• Omega-3 Fatty Acid 33%
• Creatinine 33%
• Biological Product 33%
• Side Effect 33%
• Homocysteine 33%
• Oxidoreductase 33%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 33%
• Lipoprotein 33%
• Coronary Artery Atherosclerosis 33%
• Statin (Protein) 33%
• Apolipoprotein B100 33%
• Lipoprotein A 33%
• Cholesterol Ester 33%
• Atherogenesis 33%
• Probucol 33%
• Dicarboxylic Acid 33%
• Anacetrapib 33%
• Pemafibrate 33%
• Bempedoic Acid 33%
• Gemcabene 33%
• Hypercholesterolemia 33%
• Cholesterol Ester Transfer Protein 33%
• Pitavastatin 33%